Paradigm Downgrades Biovail (BVF) to Hold
More News related to BVF
- Biovail to Participate at Upcoming Conferences
- Biovail (BVF) Tops Q3 EPS by 21c, Revs Light
- Biovail Reports Third-Quarter 2009 Financial Results
- Biovail Declares Quarterly Dividend
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
More News related to Downgrades
- Standpoint Research Downgraded Deckers Outdoor (DECK) to Hold
- BGB Securities Downgrades Helmerich & Payne (HP) to Sell
- Sidoti & Co Downgrades Waste Services (WSII) to Neutral
- William Blair Downgrades Strayer (STRA), ITT (ESI) to Market Perform
- D.A. Davidson Downgrades Rocky Brands (RCKY) to Underperform
Paradigm downgrades Biovail Corp. (NYSE: BVF) from Buy to Hold and lowers its price target from $20 to $11.25.
Biovail Corporation, a pharmaceutical company, engages in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products utilizing various drug-delivery technologies in the United States and Canada.
Related Categories
DowngradesStocks Mentioned
+0.21Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
